118 related articles for article (PubMed ID: 18305569)
1. STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy.
Wang W; Edington HD; Rao UN; Jukic DM; Wang H; Shipe-Spotloe JM; Kirkwood JM
J Invest Dermatol; 2008 Aug; 128(8):1997-2002. PubMed ID: 18305569
[TBL] [Abstract][Full Text] [Related]
2. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b.
Wang W; Edington HD; Rao UN; Jukic DM; Land SR; Ferrone S; Kirkwood JM
Clin Cancer Res; 2007 Mar; 13(5):1523-31. PubMed ID: 17332298
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma.
Wu ZS; Cheng XW; Wang XN; Song NJ
Melanoma Res; 2011 Dec; 21(6):483-90. PubMed ID: 21876460
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence imaging analysis of upstream regulators and downstream targets of STAT3 in melanoma precursor lesions obtained from patients before and after systemic low-dose interferon-alpha treatment.
Smith AP; Kirkwood JM; Edington HD; Jukic DM; Farkas DL; Becker D
Mol Imaging; 2003 Jan; 2(1):65-73. PubMed ID: 12926238
[TBL] [Abstract][Full Text] [Related]
5. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions.
Kirkwood JM; Farkas DL; Chakraborty A; Dyer KF; Tweardy DJ; Abernethy JL; Edington HD; Donnelly SS; Becker D
Mol Med; 1999 Jan; 5(1):11-20. PubMed ID: 10072444
[TBL] [Abstract][Full Text] [Related]
6. Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma.
Wang W; Edington HD; Jukic DM; Rao UN; Land SR; Kirkwood JM
Cancer Immunol Immunother; 2008 Sep; 57(9):1315-21. PubMed ID: 18386001
[TBL] [Abstract][Full Text] [Related]
7. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.
Meyer S; Wild PJ; Vogt T; Bataille F; Ehret C; Gantner S; Landthaler M; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
Exp Dermatol; 2010 Aug; 19(8):e251-7. PubMed ID: 20500769
[TBL] [Abstract][Full Text] [Related]
8. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
9. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
10. Dynamic balance of pSTAT1 and pSTAT3 in C57BL/6 mice infected with lethal or nonlethal Plasmodium yoelii.
Shi X; Qin L; Liu G; Zhao S; Peng N; Chen X
Cell Mol Immunol; 2008 Oct; 5(5):341-8. PubMed ID: 18954557
[TBL] [Abstract][Full Text] [Related]
11. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
12. A preliminary immunohistochemical study of signal transducer and activator of transcription (STAT) proteins in primary oral malignant melanoma.
Nikitakis NG; Gkouveris I; Papadopoulou E; Daskalopoulos A; Sklavounou A
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Feb; 125(2):164-171. PubMed ID: 29249519
[TBL] [Abstract][Full Text] [Related]
13. Activated stat-3 in melanoma.
Messina JL; Yu H; Riker AI; Munster PN; Jove RL; Daud AI
Cancer Control; 2008 Jul; 15(3):196-201. PubMed ID: 18596671
[TBL] [Abstract][Full Text] [Related]
14. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
Lesinski GB; Trefry J; Brasdovich M; Kondadasula SV; Sackey K; Zimmerer JM; Chaudhury AR; Yu L; Zhang X; Crespin TR; Walker MJ; Carson WE
Clin Cancer Res; 2007 Sep; 13(17):5010-9. PubMed ID: 17785551
[TBL] [Abstract][Full Text] [Related]
15. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein.
Humpoliková-Adámková L; Kovařík J; Dušek L; Lauerová L; Boudný V; Fait V; Fojtová M; Krejčí E; Kovařík A
Eur J Cancer; 2009 May; 45(7):1315-1323. PubMed ID: 19232485
[TBL] [Abstract][Full Text] [Related]
17. STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α.
Machiraju D; Moll I; Gebhardt C; Sucker A; Buder-Bakhaya K; Schadendorf D; Hassel JC
Melanoma Res; 2018 Jun; 28(3):204-210. PubMed ID: 29485532
[TBL] [Abstract][Full Text] [Related]
18. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma.
Zhuang L; Lee CS; Scolyer RA; McCarthy SW; Zhang XD; Thompson JF; Hersey P
Mod Pathol; 2007 Apr; 20(4):416-26. PubMed ID: 17384650
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression.
Tellez CS; Davis DW; Prieto VG; Gershenwald JE; Johnson MM; McCarty MF; Bar-Eli M
J Invest Dermatol; 2007 Feb; 127(2):387-93. PubMed ID: 16946713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
